Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series
Abstract
Extract Monoclonal antibodies targeting interleukin (IL)-5 (mepolizumab) or its receptor (IL-5R) (benralizumab) are biological drugs used to treat severe asthma. Both have proven efficacy in reducing exacerbations, restoring asthma control and sparing corticosteroid use, with good safety profiles [1–3]. Anti-IL-5/-5R-associated inflammatory arthritis was first reported in 2021 in six patients with severe asthma and one patient with chronic eosinophilic pneumonia [4, 5]. In our French severe asthma network CRISALIS, we have been challenged by several cases of destructive polyarthritis that developed after the initiation of anti-IL5/-5R therapies in severe asthma patients. Shareable abstract Articular manifestations should be screened before and during anti-IL-5/5R biologic treatment in severe asthma. Rigorous multidisciplinary team discussion should be carried out to assess the risk–benefit balance of withholding effective treatment. https://bit.ly/3vfPn4k
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.